Marc R. Toglia
Marc R. Toglia has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Masakazu Andoh
Rho, Inc
2 shared publicationsSergio Forero-Schwanhaeuser
GlaxoSmithKline, King Of Prussia, PA, USA
2 shared publicationsAllam Fakhoury
Astellas Pharma US, Inc
1 shared publicationChristine Laramée
1 shared publicationDonald R. Ostergard
Irvine School of Medicine
1 shared publicationIndrani M Nandy
1 shared publication
Latest Publications
- 27 January 2012
- Published by Springer Nature in International Urogynecology Journal
- Vol. 23 (9) , 1175-1176
What is the role of innovative minimally invasive surgery in today's medicine?
- 27 January 2012
- Published by Springer Nature in International Urogynecology Journal
- Vol. 23 (9) , 1175-1176
What is the role of innovative minimally invasive surgery in today's medicine?
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2277-2285
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms
It is widely recognized that patient perception of overactive bladder (OAB) symptoms can vary considerably from mild to severe bother. This post hoc analysis reports outcomes in patients with severe OAB symptoms at baseline taken from the VESIcare Efficacy and Safety in PatieNts with Urgency Study (VENUS). VENUS was a 12-week, randomized, double-blind, placebo-controlled trial of solifenacin (5 or 10 mg/day, flexibly dosed) in OAB patients. The primary endpoint in VENUS was mean change from baseline to study end in urgency episodes/day using 3-day bladder diaries. Secondary endpoints included other diary endpoints (frequency, incontinence, and nocturia), warning time (WT; time between first sensation of urgency to voiding), and patient-reported outcome (PRO) measures of urgency (the Indevus Urgency Severity Scale [IUSS] and Urgency Perception Scale [UPS]) and of symptom bother and health-related quality of life (HRQL) (the Patient Perception of Bladder Condition [PPBC] and Overactive Bladder Questionnaire). For this analysis, severe OAB was defined as baseline PPBC score ≥5 (1 = no problems, 6 = many severe problems). Trial registration: NCT00454896 In total, 158/707 (22.3%) patients in the full analysis set (FAS) reported severe OAB symptoms. Solifenacin reduced mean urgency episodes/day versus placebo in the severe subgroup (−4.6 vs. −3.1, p = 0.1150), similar to the significant reduction observed in the FAS (−3.9 vs. −2.7, p < 0.0001). Solifenacin also improved the other diary endpoints and PRO measures in the severe subgroup; these changes were consistent with the significant solifenacin- versus placebo-related improvements for the FAS. Treatment-emergent adverse events were mostly mild/moderate, and few patients taking solifenacin or placebo discontinued treatment in the severe subgroup (4.5% vs. 6.5%) or FAS (6.5% vs. 4.6%). Key limitations are that VENUS was not powered to detect treatment differences in subgroups, and that the lack of a standardized definition of OAB symptom severity may limit the generalizability of the findings. Patients with severe OAB symptoms showed objective and subjective improvements in symptoms, symptom bother, HRQL, and urgency severity with solifenacin similar to the FAS. Solifenacin was also well-tolerated in this subgroup.
- 16 August 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (10) , 2277-2285
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms
It is widely recognized that patient perception of overactive bladder (OAB) symptoms can vary considerably from mild to severe bother. This post hoc analysis reports outcomes in patients with severe OAB symptoms at baseline taken from the VESIcare Efficacy and Safety in PatieNts with Urgency Study (VENUS). VENUS was a 12-week, randomized, double-blind, placebo-controlled trial of solifenacin (5 or 10 mg/day, flexibly dosed) in OAB patients. The primary endpoint in VENUS was mean change from baseline to study end in urgency episodes/day using 3-day bladder diaries. Secondary endpoints included other diary endpoints (frequency, incontinence, and nocturia), warning time (WT; time between first sensation of urgency to voiding), and patient-reported outcome (PRO) measures of urgency (the Indevus Urgency Severity Scale [IUSS] and Urgency Perception Scale [UPS]) and of symptom bother and health-related quality of life (HRQL) (the Patient Perception of Bladder Condition [PPBC] and Overactive Bladder Questionnaire). For this analysis, severe OAB was defined as baseline PPBC score ≥5 (1 = no problems, 6 = many severe problems). Trial registration: NCT00454896 In total, 158/707 (22.3%) patients in the full analysis set (FAS) reported severe OAB symptoms. Solifenacin reduced mean urgency episodes/day versus placebo in the severe subgroup (−4.6 vs. −3.1, p = 0.1150), similar to the significant reduction observed in the FAS (−3.9 vs. −2.7, p < 0.0001). Solifenacin also improved the other diary endpoints and PRO measures in the severe subgroup; these changes were consistent with the significant solifenacin- versus placebo-related improvements for the FAS. Treatment-emergent adverse events were mostly mild/moderate, and few patients taking solifenacin or placebo discontinued treatment in the severe subgroup (4.5% vs. 6.5%) or FAS (6.5% vs. 4.6%). Key limitations are that VENUS was not powered to detect treatment differences in subgroups, and that the lack of a standardized definition of OAB symptom severity may limit the generalizability of the findings. Patients with severe OAB symptoms showed objective and subjective improvements in symptoms, symptom bother, HRQL, and urgency severity with solifenacin similar to the FAS. Solifenacin was also well-tolerated in this subgroup.
- 26 March 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (7) , 847-854
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status
VENUS evaluated the efficacy of solifenacin on urgency in patients with overactive bladder (OAB). We hypothesized that solifenacin would be comparably efficacious in continent and incontinent patients. VENUS was a 12-week, placebo-controlled trial in patients with OAB. Treatment efficacy was assessed using bladder diaries and patient-reported outcome measures. The primary endpoint was the change in daily urgency episodes. Exploratory subgroup analyses were conducted using baseline continence status. Solifenacin reduced urgency episodes versus placebo in continent (−3.4 vs. −2.3) and incontinent patients (−4.2 vs. −2.9) and incontinence episodes (−2.1 vs. −1.2) in that subgroup; 58% versus 42% of incontinent patients receiving solifenacin versus placebo were continent at study end. In both cohorts, solifenacin- versus placebo-treated patients showed greater improvements in perceptions of urgency severity, symptom bother, and health-related quality of life. This post hoc analysis demonstrates the efficacy of solifenacin regardless of baseline continence status.
- 26 March 2010
- Published by Springer Nature in International Urogynecology Journal
- Vol. 21 (7) , 847-854
Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status
VENUS evaluated the efficacy of solifenacin on urgency in patients with overactive bladder (OAB). We hypothesized that solifenacin would be comparably efficacious in continent and incontinent patients. VENUS was a 12-week, placebo-controlled trial in patients with OAB. Treatment efficacy was assessed using bladder diaries and patient-reported outcome measures. The primary endpoint was the change in daily urgency episodes. Exploratory subgroup analyses were conducted using baseline continence status. Solifenacin reduced urgency episodes versus placebo in continent (−3.4 vs. −2.3) and incontinent patients (−4.2 vs. −2.9) and incontinence episodes (−2.1 vs. −1.2) in that subgroup; 58% versus 42% of incontinent patients receiving solifenacin versus placebo were continent at study end. In both cohorts, solifenacin- versus placebo-treated patients showed greater improvements in perceptions of urgency severity, symptom bother, and health-related quality of life. This post hoc analysis demonstrates the efficacy of solifenacin regardless of baseline continence status.
- 1 September 2009
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 121 (5) , 151-158
Solifenacin for Overactive Bladder: Patient-Reported Outcomes from a Large Placebo-Controlled Trial
Objective: Overactive bladder (OAB) is a prevalent, chronic condition that can negatively affect health-related quality of life (HRQL). Treatment goals are to improve symptoms and HRQL. We assessed the efficacy of solifenacin in OAB patients using several patient-reported outcome (PRO) measures, with a focus on urgency severity. Results for the primary endpoint, reductions in daily urgency episodes, and other bladder-diary variables have been recently reported. Materials and Methods: In this 12-week multicenter trial, 739 patients (aged ⩾ 18 years) were randomized to flexibly dosed solifenacin (5/10 mg) or placebo. Prespecified secondary PRO measures included the Indevus Urgency Severity Scale (IUSS), Urgency Perception Scale (UPS), Patient Perception of Bladder Condition (PPBC), and Overactive Bladder Questionnaire (OAB-q). Appropriate statistical tests compared treatment-group differences in continuous and categorical data. Results: In the full analysis set, patients who received solifenacin (n ...
- 1 September 2009
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 121 (5) , 151-158
Solifenacin for Overactive Bladder: Patient-Reported Outcomes from a Large Placebo-Controlled Trial
Objective: Overactive bladder (OAB) is a prevalent, chronic condition that can negatively affect health-related quality of life (HRQL). Treatment goals are to improve symptoms and HRQL. We assessed the efficacy of solifenacin in OAB patients using several patient-reported outcome (PRO) measures, with a focus on urgency severity. Results for the primary endpoint, reductions in daily urgency episodes, and other bladder-diary variables have been recently reported. Materials and Methods: In this 12-week multicenter trial, 739 patients (aged ⩾ 18 years) were randomized to flexibly dosed solifenacin (5/10 mg) or placebo. Prespecified secondary PRO measures included the Indevus Urgency Severity Scale (IUSS), Urgency Perception Scale (UPS), Patient Perception of Bladder Condition (PPBC), and Overactive Bladder Questionnaire (OAB-q). Appropriate statistical tests compared treatment-group differences in continuous and categorical data. Results: In the full analysis set, patients who received solifenacin (n ...
- 5 September 2008
- Published by Springer Nature in International Urogynecology Journal
- Vol. 20 (3) , 361-362
Pyometra complicating a LeFort colpocleisis
An 81-year-old woman presented with uterine procedentia and incomplete bladder emptying. She initially experienced significant relief of her symptoms with a pessary but developed chronic vaginal bleeding and discharge. She subsequently underwent a LeFort colpocleisis. She presented to the office 7 weeks later complaining of a persistent vaginal discharge and loss of appetite. She was admitted to the hospital and was diagnosed with a pyometra and underwent a supracervical hysterectomy without complications.
- 5 September 2008
- Published by Springer Nature in International Urogynecology Journal
- Vol. 20 (3) , 361-362
Pyometra complicating a LeFort colpocleisis
An 81-year-old woman presented with uterine procedentia and incomplete bladder emptying. She initially experienced significant relief of her symptoms with a pessary but developed chronic vaginal bleeding and discharge. She subsequently underwent a LeFort colpocleisis. She presented to the office 7 weeks later complaining of a persistent vaginal discharge and loss of appetite. She was admitted to the hospital and was diagnosed with a pyometra and underwent a supracervical hysterectomy without complications.